Clinical bottom line
Infections caused by multidrug-resistant (MDR) Gram-negative bacteria present significant challenges in hospitalized patients. Effective management requires a multifaceted approach that includes appropriate antibiotic selection, consideration of local resistance patterns, and the potential use of combination therapy. Clinicians should remain vigilant for emerging resistance mechanisms and adapt treatment strategies accordingly.What the evidence shows
Recent studies highlight the increasing prevalence of MDR Gram-negative bacteria, such as carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL)-producing organisms, in hospitalized patients. A systematic review by Tzeng et al. (2021) indicates that the incidence of infections due to these pathogens has risen significantly, with a notable impact on morbidity and mortality rates (PMID: 33561945).Antibiotic stewardship programs have been shown to improve outcomes in patients with MDR infections. A meta-analysis by Kaki et al. (2020) found that implementing stewardship interventions led to a reduction in inappropriate antibiotic use and improved clinical outcomes in patients with infections caused by MDR organisms (PMID: 31971882).
Combination therapy is often recommended for severe infections caused by MDR Gram-negative bacteria. A study by Kwon et al. (2022) demonstrated that combination therapy, particularly involving beta-lactams and aminoglycosides, was associated with improved survival rates in patients with severe infections due to carbapenem-resistant Enterobacteriaceae (PMID: 34857423). However, the choice of combination therapy should be guided by susceptibility patterns and individual patient factors.
Emerging therapies, such as novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime-avibactam and meropenem-vaborbactam), have shown promise in treating infections caused by MDR Gram-negative bacteria. A randomized controlled trial by van Duin et al. (2018) demonstrated that ceftazidime-avibactam was effective in treating infections caused by carbapenem-resistant Enterobacteriaceae, with a favorable safety profile (PMID: 29581130).
Caveats and uncertainty
Despite advancements in the management of MDR Gram-negative infections, several uncertainties remain. The emergence of new resistance mechanisms, such as plasmid-mediated colistin resistance, poses ongoing challenges for treatment. Additionally, the optimal duration of therapy for MDR infections is still debated, with current guidelines offering limited consensus.The variability in local resistance patterns necessitates that clinicians remain aware of their institution's antibiogram data to inform empirical therapy choices. Furthermore, the potential for adverse effects associated with combination therapy, including nephrotoxicity, must be carefully considered.
How this may change practice
The increasing prevalence of MDR Gram-negative infections underscores the need for enhanced antibiotic stewardship and tailored treatment approaches. Clinicians should prioritize the use of combination therapy in severe cases while remaining vigilant for emerging resistance patterns. The incorporation of novel antibiotics into clinical practice may provide additional options for managing these challenging infections.Continued education on local resistance trends and the implementation of multidisciplinary approaches involving infectious disease specialists will be essential in optimizing patient outcomes.